Oncolytics Biotech (ONCY) Assets (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Assets of $7.6 million for Q4 2025, down 47.53% year-over-year from $14.5 million in Q4 2024, and down 30.7% quarter-over-quarter from $10.9 million in Q3 2025.
Oncolytics Biotech (ONCY) Assets (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Assets for 17 consecutive years, with $7.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets fell 47.53% year-over-year to $7.6 million; the TTM figure through Dec 2025 stood at $7.6 million (down 47.53% YoY), while the FY2025 annual figure was $7.6 million, down 43.51% from the prior year.
- Assets retreated to $7.6 million in Q4 2025 per ONCY's latest filing, from $10.9 million in the prior quarter.
- Across five years, Assets topped out at $45.8 million in Q2 2021 and bottomed at $7.6 million in Q4 2025.
- Historically, Assets has averaged $26.6 million across 5 years, with a median of $26.8 million in 2022.
- Annual changes were most pronounced in 2021 — Assets surged 38.16% — and 2024, when it plunged 49.32%.
- Oncolytics Biotech's Assets stood at $36.4 million in 2021, then dropped by 24.44% to $27.5 million in 2022, then increased by 3.67% to $28.5 million in 2023, then slumped by 49.32% to $14.5 million in 2024, then sank by 47.53% to $7.6 million in 2025.
- Business Quant data shows ONCY's Assets at $7.6 million in Q4 2025, $10.9 million in Q3 2025, and $14.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 19.82 Bn |
| 10 | Oncolytics Biotech | 98.70 Mn | 98.70 Mn | - | 7.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.67 Mn |
| Dec 31, 2025 | 7.58 Mn |
| Sep 30, 2025 | 10.94 Mn |
| Jun 30, 2025 | 14.42 Mn |
| Mar 31, 2025 | 13.73 Mn |
| Dec 31, 2024 | 14.45 Mn |
| Sep 30, 2024 | 17.79 Mn |
| Jun 30, 2024 | 23.45 Mn |
| Mar 31, 2024 | 25.79 Mn |
| Dec 31, 2023 | 28.51 Mn |
| Sep 30, 2023 | 34.38 Mn |
| Jun 30, 2023 | 23.80 Mn |
| Mar 31, 2023 | 26.13 Mn |
| Dec 31, 2022 | 27.50 Mn |
| Sep 30, 2022 | 29.87 Mn |
| Jun 30, 2022 | 31.56 Mn |
| Mar 31, 2022 | 35.09 Mn |
| Dec 31, 2021 | 36.40 Mn |
| Sep 30, 2021 | 41.78 Mn |
| Jun 30, 2021 | 45.81 Mn |